Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: Recent developments

Current Hematologic Malignancy Reports

Volumn 7, Issue 2, 2012, Pages 133-143

  Iacobucci, Ilaria ^a   Papayannidis, Cristina ^a   Lonetti, Annalisa ^a   Ferrari, Anna ^a   Baccarani, Michele ^a   Martinelli, Giovanni ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Acute lymphoblastic leukemia; ALL; Next generation sequencing; SNP array

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; B CELL LEUKEMIA; CANCER GENETICS; CYTOGENETICS; HUMAN; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; RISK FACTOR; T CELL LEUKEMIA;

CYTOGENETIC ANALYSIS; GENE EXPRESSION PROFILING; GENOME, HUMAN; HUMANS; MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SEQUENCE ANALYSIS, DNA;

EID: 84860841656     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-012-0122-5     Document Type: Article

References (100)

1. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood. 2004;104:2690-6. (Pubitemid 39434949)
2. Bassan R. Evolving strategies for the management of high-risk adult acute lymphoblastic leukemia. Haematologica. 2005;90:1299.
3. Andreasson P, Schwaller J, Anastasiadou E, et al. The expression of ETV6/CBFA2 (TEL/AML1) is not sufficient for the transformation of hematopoietic cell lines in vitro or the induction of hematologic disease in vivo. Cancer Genet Cytogenet. 2001;130:93-104. (Pubitemid 33033225)
4. Williams RT, Roussel MF, Sherr CJ. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2006;103:6688-93.
5. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446:758-64. (Pubitemid 46582031)
6. Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109:3189-97. (Pubitemid 46572503)
7. A Collaborative Study of the Group Francais de Cytogenetique Hematologique. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. Blood. 1996;87:3135-42.
8. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371:1030-43. (Pubitemid 351389536)
9. Soverini S, Colarossi S, Gnani A, et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica. 2007;92:401-4. (Pubitemid 350143551)
10. Devaraj PE, Foroni L, Janossy G, et al. Expression of the E2APBX1 fusion transcripts in t (1;19) (q23;p13) and der (19)t (1;19) at diagnosis and in remission of acute lymphoblastic leukemia with different B lineage immunophenotypes. Leukemia. 1995;9:821-5.
11. Foa R, Vitale A, Mancini M, et al. E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. Br J Haematol. 2003;120:484-7. (Pubitemid 36241507)
12. Romana SP, Poirel H, Leconiat M, et al. High frequency of t (12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood. 1995;86:4263-9.
13. Raimondi SC, Pui CH, Hancock ML, et al. Heterogeneity of hyperdiploid (51-67) childhood acute lymphoblastic leukemia. Leukemia. 1996;10:213-24. (Pubitemid 26102884)
14. Harrison CJ, Moorman AV, Broadfield ZJ, et al. Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. Br J Haematol. 2004;125:552-9. (Pubitemid 38747956)
15. Iacobucci I, Storlazzi CT, Cilloni D, et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1- positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood. 2009;114:2159-67.
16. Kuiper RP, Schoenmakers EF, van Reijmersdal SV, et al. Highresolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia. 2007;21:1258-66. (Pubitemid 46831815)
17. Iacobucci I, Lonetti A, Paoloni F, et al. The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome A report on behalf of the GIMEMA Acute Leukemia Working Party. Haematologica. 2010;95:1683-90.
18. Iacobucci I, Ferrari A, Lonetti A, et al. CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. Clin Cancer Res. 2011;17:7413-23. In adult BCR-ABL1 positive ALL CDKN2A/B deletions represent a frequent event and they are frequently acquired during leukemia progression. Deletions are significantly associated with poor outcomes in terms of overall survival, disease free-survival, and cumulative incidence of relapse.
19. Trageser D, Iacobucci I, Nahar R, et al. Pre-B cell receptormediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. J Exp Med. 2009;206:1739-53.
20. Diouf B, Cheng Q, Krynetskaia NF, et al. Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat Med. 2011;17:1298-303.
21. Georgopoulos K, Bigby M, Wang JH, et al. The Ikaros gene is required for the development of all lymphoid lineages. Cell. 1994;79:143-56. (Pubitemid 24309520)
22. Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453:110-4. (Pubitemid 351630327)
23. Iacobucci I, Lonetti A, Messa F, et al. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood. 2008;112:3847-55.
24. Cazzaniga G, van Delft FW, Lo Nigro L, et al. Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+acute lymphoblastic leukemia. Blood. 2011;118:5559-64.
25. Tonnelle C, Dijon M, Moreau T, et al. Stage specific overexpression of the dominant negative Ikaros 6 reveals distinct role of Ikaros throughout human B-cell differentiation. Mol Immunol. 2009;46:1736-43.
26. Virely C, Moulin S, Cobaleda C, et al. Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCRABL in a transgenic model of acute lymphoblastic leukemia. Leukemia. 2010;24:1200-4.
27. Kuiper RP, Waanders E, van der Velden VH, et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor BALL. Leukemia. 2010;24:1258-64.
28. Martinelli G, Iacobucci I, Storlazzi CT, et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: aGIMEMAALWP report. J ClinOncol. 2009;27:5202-7.
29. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360:470-80.
30. Waanders E, van der Velden VH, van der Schoot CE, et al. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79 % of relapses in pediatric acute lymphoblastic leukemia. Leukemia; 2010.
31. Yang YL, Hung CC, Chen JS, et al. IKZF1 deletions predict a poor prognosis in children with B-cell progenitor acute lymphoblastic leukemia: a multicenter analysis in Taiwan. Cancer Sci. 2011;102:1874-81
32. Venn NC, van der Velden VH, de Bie M, et al. Highly sensitive MRD tests for ALL based on the IKZF1 Delta3-6 microdeletion. Leukemia; 2011.
33. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. Asubtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10:125-34.
34. Busslinger M. Transcriptional control of early B cell development. Annu Rev Immunol. 2004;22:55-79. (Pubitemid 38680418)
35. Familiades J, Bousquet M, Lafage-Pochitaloff M, et al. PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study. Leukemia; 2009.
36. Nebral K, Denk D, Attarbaschi A, et al. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia. 2009;23:134-43.
37. Faderl S, Estrov Z, Kantarjian HM, et al. The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15 (INK4b)/p16 (INK4a)/p14 (ARF) in patients with acute lymphoblastic leukemia. Cytokines Cell Mol Ther. 1999;5:159-63. (Pubitemid 29481353)
38. Heyman M, Rasool O, Borgonovo Brandter L, et al. Prognostic importance of p15INK4B and p16INK4 gene inactivation in childhood acute lymphocytic leukemia. J Clin Oncol. 1996;14:1512-20.
39. Notta F, Mullighan CG, Wang JC, et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature. 2011;469:362-7.
40. Russell LJ, Capasso M, Vater I, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood. 2009;114:2688-98.
41. Mullighan CG, Collins-Underwood JR, Phillips LA, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndromeassociated acute lymphoblastic leukemia. Nat Genet. 2009; 41:1243-6.
42. Hertzberg L, Vendramini E, Ganmore I, et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood. 2010;115:1006-17.
43. Yoda A, Yoda Y, Chiaretti S, et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2010;107:252-7.
44. Liu YJ. TSLP in epithelial cell and dendritic cell cross talk. Adv Immunol. 2009;101:1-25.
45. Levin SD, Koelling RM, Friend SL, et al. Thymic stromal lymphopoietin: a cytokine that promotes the development of IgM+Bcells in vitro and signals via a novel mechanism. J Immunol. 1999;162:677-83. (Pubitemid 29035386)
46. Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric Bprogenitor acute lymphoblastic leukemia. Blood. 2010;115:5312-21.
47. Cario G, Zimmermann M, Romey R, et al. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood. 2010;115:5393-7.
48. Harrison CJ, Moorman AV, Barber KE, et al. Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukaemia: a UK Cancer Cytogenetics Group Study. Br J Haematol. 2005;129:520-30. (Pubitemid 40769901)
49. Rand V, Parker H, Russell LJ, et al. Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia. Blood. 2011;117:6848-55.
50. Moorman AV, Richards SM, Robinson HM, et al. Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood. 2007;109:2327-30. (Pubitemid 46425871)
51. Attarbaschi A, Mann G, Panzer-Grumayer R, et al. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. JClin Oncol. 2008;26:3046-50.
52. Soverini S, Vitale A, Poerio A, et al. Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. Haematologica. 2011;96:552-7.
53. Zhang J, Mullighan CG, Harvey RC, et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2011;118:3080-7.
54. Mullighan CG, Zhang J, Kasper LH, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature. 2011;471:235-9. Mutations of CREBBP, occurring 8.3 % of relapse B-ALL, are either present at diagnosis or acquired at relapse, and resulted in truncated alleles or deleterious substitutions in conserved residues of the histone acetyltransferase domain that impair histone acetylation and transcriptional regulation of CREBBP targets, including glucocorticoid responsive genes.
55. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769-84. (Pubitemid 44348499)
56. Hof J, Krentz S, van Schewick C, et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol. 2011;29:3185-93.
57. Lilljebjorn H, Rissler M, Lassen C, et al. Whole-exome sequencing of pediatric acute lymphoblastic leukemia. Leukemia; 2011.
58. Iacobucci I, Ferrarini A, Sazzini M, et al. Application of the whole transcriptome shotgun sequencing approach to the study of philadelphia-positive acute lymphoblastic leukemia. Blood Cancer Journal; 2012.
59. Carroll AJ, Crist WM, Link MP, et al. The t (1;14) (p34;q11) is nonrandom and restricted to T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood. 1990;76:1220-4. (Pubitemid 20318168)
60. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1:75-87. (Pubitemid 41039178)
61. van Oostveen J, Bijl J, Raaphorst F, et al. The role of homeobox genes in normal hematopoiesis and hematological malignancies. Leukemia. 1999;13:1675-90. (Pubitemid 29535248)
62. Soulier J, Clappier E, Cayuela JM, et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood. 2005;106:274-86. (Pubitemid 40967203)
63. Speleman F, Cauwelier B, Dastugue N, et al. A new recurrent inversion, inv (7) (p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias. Leukemia. 2005;19:358-66. (Pubitemid 40403311)
64. Bernard OA, Busson-LeConiat M, Ballerini P, et al. A new recurrent and specific cryptic translocation, t (5;14) (q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia. Leukemia. 2001;15:1495-504. (Pubitemid 32994666)
65. Tycko B, Smith SD, Sklar J. Chromosomal translocations joining LCK and TCRB loci in human T cell leukemia. J Exp Med. 1991;174:867-73.
66. Clappier E, Cuccuini W, Cayuela JM, et al. Cyclin D2 dysregulation by chromosomal translocations to TCR loci in T-cell acute lymphoblastic leukemias. Leukemia. 2006;20:82-6.
67. Karrman K, Kjeldsen E, Lassen C, et al. The t (X;7) (q22;q34) in paediatric T-cell acute lymphoblastic leukaemia results in overexpression of the insulin receptor substrate 4 gene through illegitimate recombination with the T-cell receptor beta locus. Br JHaematol. 2009;144:546-51.
68. Rowe JM. Prognostic factors in adult acute lymphoblastic leukaemia. Br J Haematol. 2010;150:389-405.
69. Van Vlierberghe P, van Grotel M, Tchinda J, et al. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood. 2008;111:4668-80.
70. Zipfel PA, Zhang W, Quiroz M, et al. Requirement for Abl kinases in T cell receptor signaling. Curr Biol. 2004;14:1222-31. (Pubitemid 38991808)
71. Hagemeijer A, Graux C. ABL1 rearrangements in T-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2010;49:299-308.
72. Flex E, Petrangeli V, Stella L, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med. 2008;205:751-8. (Pubitemid 351549874)
73. Otsubo K, Kanegane H, Eguchi M, et al. ETV6-ARNT fusion in apatient with childhood T lymphoblastic leukemia. Cancer Genet Cytogenet. 2010;202:22-6.
74. Lahortiga I, De Keersmaecker K, Van Vlierberghe P, et al. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet. 2007;39:593-5. (Pubitemid 46676109)
75. Hebert J, Cayuela JM, Berkeley J, et al. Candidate tumorsuppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from Tbut not from B-cell lineage acute lymphoblastic leukemias. Blood. 1994;84:4038-44.
76. Palomero T, Sulis ML, Cortina M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007;13:1203-10. (Pubitemid 47530629)
77. Maser RS, Choudhury B, Campbell PJ, et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature. 2007;447:966-71. (Pubitemid 46975753)
78. O'Neil J, Grim J, Strack P, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med. 2007;204:1813-24. (Pubitemid 47236319)
79. Ferrando A. NOTCH mutations as prognostic markers in T-ALL. Leukemia. 2010;24:2003-4.
80. Balgobind BV, Van Vlierberghe P, van den Ouweland AM, et al. Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood. 2008;111:4322-8.
81. Van Vlierberghe P, Meijerink JP, Stam RW, et al. Activating FLT3 mutations in CD4+/CD8- pediatric T-cell acute lymphoblastic leukemias. Blood. 2005;106:4414-5. (Pubitemid 41775958)
82. Paietta E, Ferrando AA, Neuberg D, et al. Activating FLT3 mutations in CD117/KIT (+) T-cell acute lymphoblastic leukemias. Blood. 2004;104:558-60. (Pubitemid 38900041)
83. Kleppe M, Lahortiga I, El Chaar T, et al. Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat Genet. 2010;42:530-5.
84. Remke M, Pfister S, Kox C, et al. High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. Blood. 2009;114:1053-62.
85. Van Vlierberghe P, Palomero T, Khiabanian H, et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet. 2010;42:338-42.
86. Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481:157-63. Zhang and colleagues performed whole genome sequencing of 12 ETPALL cases identifying activating mutations in genes regulating cytokine receptor and RAS signaling (67 %), inactivating lesions disrupting hematopoietic development (58 %), and histone-modifying genes (48 %). Gene expression profile of ETP ALL resulted similar to that of normal and myeloid leukemia hematopoietic stem cells, suggesting the possibility that myeloiddirected therapies might improve the poor outcome of ETPALL.
87. Sulong S, Moorman AV, Irving JA, et al. A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups. Blood. 2009;113:100-7.
88. Mullighan CG, Williams RT, Downing JR, et al. Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. Genes Dev. 2008;22:1411-5. (Pubitemid 351793074)
89. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306:269-71. (Pubitemid 39336870)
90. Breit S, Stanulla M, Flohr T, et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood. 2006;108:1151-7. (Pubitemid 44232009)
91. Asnafi V, Buzyn A, Le Noir S, et al. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood. 2009;113:3918-24.
92. Baldus CD, Thibaut J, Goekbuget N, et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute Tlymphoblastic leukemia. Haematologica. 2009;94:1383-90.
93. Gutierrez A, Sanda T, Grebliunaite R, et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood. 2009;114:647-50.
94. Yamada Y, Hatta Y, Murata K, et al. Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia. J Clin Oncol. 1997;15:1778-85. (Pubitemid 27209504)
95. Fizzotti M, Cimino G, Pisegna S, et al. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood. 1995;85:2685-90.
96. Markaki EA, Stiakaki E, Zafiropoulos A, et al. Mutational analysis of the cell cycle inhibitor Kip1/p27 in childhood leukemia. Pediatr Blood Cancer. 2006;47:14-21. (Pubitemid 43787903)
97. Tosello V, Mansour MR, Barnes K, et al. WT1 mutations in TALL. Blood. 2009;114:1038-45.
98. Renneville A, Kaltenbach S, Clappier E, et al. Wilms tumor 1 (WT1) gene mutations in pediatric T-cell malignancies. Leukemia. 2010;24:476-80.
99. Gutierrez A, Sanda T, Ma W, et al. Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood. 2010;115:2845-51.
100. Kleppe M, Soulier J, Asnafi V, et al. PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia. Blood. 2011;117:7090-8.